1 citations
,
November 2023 in “Journal of Investigative Dermatology” Farudodstat may effectively treat alopecia areata without harming hair follicles.
4 citations
,
July 2024 in “The Journal of Dermatology” Alopecia areata in Dubai mostly affects men, often involves autoimmune disorders, and has high healthcare costs, especially for psychological issues.
January 2026 in “AIP conference proceedings”
Androgenetic alopecia is not linked to higher risks of hypertension or hyperaldosteronism.
1 citations
,
August 2023 in “Journal of Investigative Dermatology” Farudodstat may help treat alopecia areata by protecting hair follicles.
5 citations
,
December 2024 in “Patient Preference and Adherence” Patients with alopecia areata in Saudi Arabia understand the condition's seriousness but still face significant psychological challenges.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
48 citations
,
July 2023 in “Pediatric Dermatology” Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.
August 2016 in “Journal of Investigative Dermatology”
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
September 2023 in “Journal of The American Academy of Dermatology” Adolescents with hair loss show different hormone levels by sex and often have related metabolic issues.
November 2025 in “Open Repository of the University of Porto (University of Porto)” Pharmacists play a crucial role in customizing treatments and ensuring medication safety.
December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
1 citations
,
June 2026 in “Dermato” Ritlecitinib is effective for treating alopecia areata, showing significant hair regrowth with mild side effects.
88 citations
,
March 2004 in “Journal of Investigative Dermatology” February 2025 in “Pediatric Dermatology” January 2013 in “Annals of King Edward Medical University” Androgenetic alopecia negatively impacts quality of life, especially for women, due to social reactions.
March 2005 in “Journal of the American Academy of Dermatology” Higher levels of IL-1a and IL-1RA were found in severe alopecia areata cases.
2 citations
,
May 2024 in “International Journal of Medical Arts” Diphenylcyclopropenone (DPCP) is more effective than anthralin for treating resistant alopecia areata.
July 2026 in “Journal of the American Academy of Dermatology”
June 2026 in “International Journal of Dermatology Venereology and Leprosy Sciences” Alopecia areata patients may have higher blood pressure and blood sugar, indicating a future risk of metabolic issues.
September 2017 in “Majallah-i taḥqīqāt-i ̒ulūm-i pizishkī-i Zāhidān” Androgenetic alopecia is a long-term, immune-related disorder that starts during puberty due to androgen secretion, and it might be improved with iron tablets, platelet transfusion, and anti-inflammation therapy.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Abatacept may help some people with alopecia areata regrow hair.
15 citations
,
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
The levels of zinc, vitamin D, ferritin, and selenium are different in people with androgenic alopecia compared to a control group.
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
Medieval poultices by Abulcasis were used to treat hair loss.
February 2026 in “Journal of Drugs in Dermatology” Dupilumab helped a 13-year-old regrow hair after alopecia totalis.
4 citations
,
January 2011 in “Dermatopathology”
June 2024 in “Frontiers in immunology” Sequential therapy with dupilumab and baricitinib improved hair regrowth and atopic dermatitis in a child without adverse reactions.